Status Epilepticus

Status Epilepticus – High‑Yield Study Guide for Medical Students

Definition

Status epilepticus (SE) is a neurological emergency characterized by prolonged or rapidly recurrent seizures with a risk of irreversible neuronal injury and death. Modern, operational definitions are time-based to trigger early treatment:

• Generalized convulsive SE (GCSE): a tonic–clonic seizure lasting ≥5 minutes, or >=2 seizures without full return to baseline consciousness between events.
• Nonconvulsive SE (NCSE): continuous or near-continuous ictal EEG activity with altered mental status for ≥10–15 minutes (or recurrent episodes) without recovery.
• Refractory SE (RSE): SE that persists despite adequate initial benzodiazepine plus one appropriately dosed second-line antiseizure drug.
• Super‑refractory SE (SRSE): SE that continues or recurs >24 hours after initiation of anesthetic therapy, including during or after attempts to wean anesthetics. [1]

The critical concept for exams and clinical care is that you treat at 5 minutes; do not wait 30 minutes to label SE before initiating aggressive therapy.

Epidemiology

Status epilepticus is common in emergency and critical care settings and is associated with substantial morbidity and mortality.

• Incidence: Approximately 10–60 cases per 100,000 person‑years, varying by age, etiology, and region.
• Age distribution: Bimodal, with highest incidence in young children and older adults.
• Mortality: Often quoted in the 10–30% range overall, strongly dependent on etiology (e.g., anoxic brain injury, stroke, CNS infection) and time to seizure control. [1]
• Global considerations: Mortality and disability from SE are disproportionately higher in low‑ and middle‑income countries due to limited access to timely treatment, continuous EEG, and intensive care support. [2]

Pathophysiology

SE represents failure of normal mechanisms that terminate seizures, plus the emergence of processes that sustain ongoing epileptic activity.

• Early phase (minutes):
  • Excessive glutamatergic excitation and insufficient GABAergic inhibition.
  • Increased neuronal firing, elevated cerebral metabolic demand, and increased cerebral blood flow.
  • Systemic sympathetic surge: tachycardia, hypertension, hyperthermia, hyperglycemia, lactic acidosis.
• Established phase (>~30 minutes):
  • Receptor trafficking: internalization of synaptic GABA_A receptors and increased expression of excitatory NMDA/AMPA receptors, which reduces benzodiazepine responsiveness and promotes pharmacoresistance.
  • Breakdown of the blood–brain barrier and release of inflammatory mediators.
  • Calcium influx, mitochondrial dysfunction, oxidative stress, and apoptotic/necrotic neuronal death.
• Systemic consequences:
  • Hypoxia and hypercapnia from impaired ventilation and airway compromise.
  • Rhabdomyolysis, hyperkalemia, metabolic acidosis.
  • Arrhythmias, hypotension (especially later and with sedatives), aspiration, and multi‑organ dysfunction.

The longer seizures persist, the more difficult they become to terminate and the higher the risk of neuronal injury, emphasizing the need for early, protocolized treatment. [3]

Etiology and Precipitating Factors

SE is a syndrome with multiple possible causes. Identifying the underlying etiology is essential for targeted treatment and prognosis.

• CNS structural & vascular causes
  • Acute stroke (ischemic or hemorrhagic).
  • Traumatic brain injury.
  • Brain tumors or metastases.
  • Post‑neurosurgical states.
• Infectious & inflammatory
  • Meningitis, encephalitis (e.g., HSV, autoimmune encephalitis).
  • Brain abscess.
  • Systemic infection with sepsis.
• Metabolic & systemic
  • Hypoglycemia, hyperglycemia (including HHS, DKA).
  • Hyponatremia, hypernatremia, hypocalcemia, hypomagnesemia.
  • Uremia, hepatic failure, hypoxia.
• Toxic & withdrawal
  • Alcohol withdrawal (classic cause of generalized tonic–clonic SE).
  • Withdrawal of benzodiazepines or barbiturates.
  • Cocaine, amphetamines, isoniazid, theophylline, organophosphates, other intoxications.
• Epilepsy‑related
  • Medication non‑adherence or abrupt discontinuation of antiseizure drugs.
  • Progression of underlying epilepsy syndromes.
• Autoimmune & paraneoplastic
  • Anti‑NMDA receptor encephalitis, LGI1, CASPR2, GAD65, and other antibody‑mediated diseases.
• Idiopathic / cryptogenic when no cause is found despite evaluation.

Clinical Presentation

Presentation varies depending on seizure type and level of consciousness. Always evaluate ABCs (airway, breathing, circulation) first.

Generalized Convulsive Status Epilepticus (GCSE)

• Motor activity:
  • Recurrent or continuous generalized tonic–clonic movements (tonic stiffening followed by clonic jerking).
  • Can evolve into subtle motor signs (e.g., facial or eyelid twitching, nystagmus, small myoclonic jerks) especially after paralytics or in prolonged SE.
• Consciousness: Impaired or absent; patient typically unresponsive.
• Autonomic changes: Tachycardia, hypertension (early), diaphoresis, hyperthermia, hypersalivation.
• Postictal phase: May be absent or not observable due to continuous or rapidly recurring seizures.

Nonconvulsive Status Epilepticus (NCSE)

NCSE is common in the ICU and is easily missed without EEG. It includes absence SE, focal impaired awareness SE, and post‑convulsive NCSE.

• Altered mental status:
  • Fluctuating or persistent confusion, agitation, delirium, or coma.
  • Can present as subtle behavior changes in older adults.
• Minimal or subtle motor signs:
  • Eye deviation, nystagmus, facial twitching, myoclonic jerks, automatisms (lip smacking, picking).
  • Sometimes completely nonmotor.
• Context:
  • Often seen after apparent termination of a convulsive seizure, in comatose ICU patients, or in patients with previous epilepsy or brain injury.

Key Initial Clinical Priorities

• Rapidly assess airway, breathing, circulation.
• Check rapid point‑of‑care glucose; treat hypoglycemia immediately.
• Obtain vital signs, oxygen saturation, and secure IV access.
• Start timekeeping – document when seizure started and when each treatment is given.

Diagnosis

Diagnosis is primarily clinical, supported by EEG and investigations to identify the underlying cause.

Clinical Diagnosis

• History:
  • Witness description (onset, duration, focal vs generalized, triggers).
  • Past history of epilepsy, recent trauma, stroke, infection, alcohol/benzodiazepine use.
  • Medication list, adherence, recent dosage changes.
• Examination:
  • Neurologic status (GCS, focal deficits), pupillary responses, signs of trauma or meningism.
  • Cardiopulmonary status; aspiration risk; signs of infection or systemic illness.

Electroencephalography (EEG)

• Indications:
  • Suspected NCSE (altered mental status not explained by imaging/metabolic causes).
  • Post‑convulsive coma without clear clinical seizures.
  • Refractory SE receiving anesthetic infusions (for monitoring burst suppression and seizure suppression).
• Role:
  • Confirms ongoing electrographic seizures or periodic discharges consistent with SE.
  • Allows tailoring of antiseizure and anesthetic dosing to suppress ictal activity.
  • Continuous EEG in the ICU can detect otherwise occult seizures and guide ongoing management. [4]

Laboratory Evaluation

Laboratory workup aims to identify reversible metabolic or toxic causes and assess complications.

• Immediate tests:
  • Point‑of‑care blood glucose.
  • Serum electrolytes (Na, K, Ca, Mg), renal and liver function tests.
  • Complete blood count, blood gas, lactate.
  • Toxicology screen and specific drug levels (e.g., antiseizure drugs, alcohol, salicylate, acetaminophen) as available.
• Extended tests (as indicated):
  • Coagulation profile, ammonia, autoimmune and paraneoplastic panels.
  • Cultures (blood, urine) if infection suspected.
  • Cerebrospinal fluid analysis if meningitis/encephalitis considered and no contraindication to LP.

Neuroimaging

• CT head (non‑contrast):
  • First‑line in the emergency setting for suspected hemorrhage, mass effect, or large stroke.
• MRI brain:
  • Higher sensitivity for early ischemia, encephalitis, subtle structural lesions, and status‑related changes.
  • Useful in subacute evaluation after stabilization to identify underlying etiology.

Management Overview

Management of SE is time‑critical and protocol‑driven. Think in stages: initial stabilization, emergent treatment, urgent control therapy, refractory and super‑refractory strategies. Guidelines emphasize early benzodiazepines, rapid escalation, and systematic etiology workup. [3]

Step 1: Immediate Stabilization (0–5 minutes)

• Airway:
  • Position patient, clear secretions, use jaw thrust, high‑flow oxygen.
  • Prepare for intubation if persistent seizures, hypoventilation, or decreased protective reflexes.
• Breathing:
  • Monitor SpO₂, respiratory rate; provide bag‑mask ventilation if needed.
• Circulation:
  • Monitor heart rate, blood pressure, establish IV or IO access.
  • Begin isotonic fluid resuscitation if hypotensive.
• Glucose and thiamine:
  • Check finger‑stick glucose; if low, administer IV dextrose (e.g., 25 g D50 in adults).
  • In at‑risk patients (e.g., chronic alcohol use, malnutrition), give IV thiamine before or with glucose.

Step 2: First‑Line Emergent Therapy (within 5 minutes)

Benzodiazepines are the first‑line therapy for SE. Early adequate dosing is crucial to terminate seizures and prevent progression to refractory SE. [3]

• IV Lorazepam (preferred when IV access available)
  • Typical dosing: 0.1 mg/kg IV (maximum 4 mg per dose), may repeat once after 5–10 minutes if seizures persist.
  • Longer CNS duration of action compared with diazepam.
• IV Diazepam
  • 0.15–0.2 mg/kg IV (up to 10 mg/dose), repeat once if needed.
  • Rapid onset but shorter CNS duration; follow with longer‑acting antiseizure drug.
• IM Midazolam (if no IV access)
  • Typical dose: 10 mg IM in adults (adjust per weight in children).
  • Alternative routes: intranasal or buccal midazolam, or rectal diazepam in prehospital/field settings.

Step 3: Second‑Line Urgent Therapy (10–30 minutes)

If seizures continue after appropriate benzodiazepine dosing, initiate a second‑line antiseizure medication. Evidence supports several reasonable options; selection often depends on local protocols and patient factors. [3]

• Options for IV loading (adult dosing examples):
  • Levetiracetam: 40–60 mg/kg IV (often 3,000–4,500 mg), infused over 10–15 minutes.
  • Valproate (valproic acid): 20–40 mg/kg IV (max ~3,000 mg), caution in liver disease, mitochondrial disorders, pregnancy.
  • Fosphenytoin / Phenytoin: Fosphenytoin 20 mg PE/kg IV (up to 150 mg PE/min), cardiac monitoring required due to hypotension and arrhythmia risk.
  • Lacosamide: 200–400 mg IV load (up to 10 mg/kg) as an alternative in some protocols.
• Brivaracetam:
  • Newer option increasingly used with evolving evidence for SE, generally as an adjunct or alternative second‑line agent. [5]

Step 4: Refractory Status Epilepticus (RSE)

RSE is defined as SE that continues despite adequate benzodiazepine and at least one appropriately dosed second‑line antiseizure medication. These patients typically require ICU admission, continuous EEG, and anesthetic infusions. [1]

• Anesthetic options:
  • Midazolam infusion (e.g., 0.05–2 mg/kg/h after a loading bolus).
  • Propofol infusion (e.g., 2–10 mg/kg/h following a bolus), with attention to hemodynamics and risk of propofol infusion syndrome.
  • Barbiturate coma (e.g., pentobarbital) with goal of EEG burst suppression; associated with hemodynamic instability and need for vasopressors.
  • Ketamine infusion, a NMDA receptor antagonist, is used in many centers for RSE/SRSE, particularly when GABAergic approaches have failed. Case series show efficacy in some refractory cases. [6]
• Monitoring:
  • Continuous EEG to guide dosing (aim for seizure suppression, often burst suppression for 24–48 hours).
  • Invasive hemodynamic monitoring, ventilatory support, frequent metabolic and organ function assessment.

Step 5: Super‑Refractory Status Epilepticus (SRSE)

SRSE persists despite ongoing anesthetic treatment or recurs upon weaning. Management is highly individualized and often multimodal. [1]

• Adjunctive pharmacologic strategies:
  • Further optimization of antiseizure drug combinations (e.g., adding topiramate, perampanel, phenobarbital, ketamine if not used previously).
  • Immunotherapy if autoimmune encephalitis suspected (e.g., high‑dose steroids, IVIG, plasmapheresis, rituximab in selected cases).
  • Ketogenic diet in select pediatric and adult patients.
• Surgical and device‑based options:
  • Focal resective epilepsy surgery when a discrete epileptogenic lesion/zone is identified.
  • Disconnection procedures (e.g., corpus callosotomy) in select patterns of generalized or multifocal seizures.
  • Neuromodulation (vagus nerve stimulation, responsive neurostimulation, deep brain stimulation) as adjunctive therapy in chronic or recurrent refractory seizures.
  • Evidence from systematic reviews suggests that surgery can be an effective rescue therapy in carefully selected SRSE cases. [7]

Supportive and Etiology‑Directed Management

Alongside seizure control, treat complications and underlying causes.

• Supportive care:
  • Airway protection, mechanical ventilation as needed.
  • Temperature control (treat fever, avoid hyperthermia).
  • Prevention and treatment of rhabdomyolysis (aggressive hydration, monitor CK and renal function).
  • Thromboprophylaxis, pressure sore prevention, nutritional support.
• Etiology‑specific therapy:
  • Antibiotics/antivirals for CNS or systemic infections.
  • Reversal or correction of metabolic derangements (electrolyte abnormalities, hypoglycemia, DKA/HHS, etc.).
  • Thrombolysis or thrombectomy where indicated for acute ischemic stroke within time window.
  • Immunotherapy for autoimmune encephalitis.
  • Withdrawal management (benzodiazepines, supportive care) for alcohol or benzodiazepine withdrawal.

Status Epilepticus in Resource‑Limited Settings

In low‑resource environments, management must adapt to limited EEG, ICU capacity, and medication availability. Expert surveys suggest prioritizing early benzodiazepines, pragmatic second‑line choices (e.g., phenobarbital, phenytoin, valproate where available), and simple, standardized treatment algorithms that staff can implement rapidly. [2]

• Use locally available benzodiazepine routes (IM, intranasal, buccal) if IV access delayed.
• Choose second‑line agents based on cost, availability, and clinician familiarity.
• Basic monitoring (vital signs, point‑of‑care glucose) and prompt transfer to higher level of care when feasible.

Complications and Prognosis

• Neurologic complications:
  • Permanent cognitive impairment, focal neurologic deficits, chronic epilepsy.
  • Increased risk of neuronal loss, especially in hippocampus and other vulnerable regions.
• Systemic complications:
  • Aspiration pneumonia, ARDS, sepsis.
  • Rhabdomyolysis, acute kidney injury.
  • Cardiac arrhythmias, hypotension, multi‑organ failure.
• Prognostic factors:
  • Etiology (anoxic brain injury and CNS infections carry particularly poor prognosis).
  • Duration of SE before control.
  • Age and baseline neurological status.
  • Level of consciousness at presentation and EEG background.

Key Clinical Pearls for Exams and Wards

• Treat at 5 minutes: Do not wait 30 minutes to label SE; early benzodiazepines improve outcomes.
• Adequate benzo dosing: Under‑dosing is common and associated with progression to RSE; use weight‑based doses.
• Always check glucose: Hypoglycemia is fast, reversible, and easily missed.
• Think NCSE: Any unexplained coma or persistent postictal state warrants consideration of NCSE and EEG.
• Etiology matters: Outcome is more dependent on cause than on seizure type alone; aggressively search for underlying pathology.
• Use a protocol: Standardized SE pathways (benzodiazepine → second‑line load → anesthetic if refractory) reduce treatment delays and variability. [3]
• Continuous EEG in ICU: Essential for detecting ongoing electrographic seizures and guiding therapy in RSE/SRSE. [4]
• Consider SRSE tools: Ketamine, immunotherapy, ketogenic diet, and, in selected patients, surgical options can be life‑saving in super‑refractory cases. [6][7]

Summary

Status epilepticus is a time‑critical neurological emergency defined by prolonged or rapidly recurrent seizures, with risk of permanent brain injury and death. The pillars of management are early recognition, immediate stabilization, prompt benzodiazepine administration, rapid initiation of second‑line antiseizure medications, escalation to anesthetic coma for refractory cases, and identification and treatment of the underlying etiology. Protocolized care, continuous EEG monitoring where available, and tailored management in resource‑limited settings are central to improving outcomes. [3][2]